Heart failure with preserved left ventricular ejection fraction

Czech version

Authors: H. Hrabáková; M. Pěnička
Authors‘ workplace: Přednosta: prof. MUDr. Petr Widimský, DrSc. ; Fakultní nemocnice Královské Vinohrady, Praha ; III. interní-kardiologická klinika Kardiocentra ; Univerzita Karlova v Praze, 3. lékařská fakulta
Published in: Prakt. Lék. 2008; 88(7): 396-397
Category: Of different specialties

Overview

This review summarizes the current knowledge on prevalence, diagnosis, prognosis and treatment in heart failure with preserved left ventricular ejection fraction. Prevalence of heart failure in Europe is increasing and at least 50 % of patients with heart failure have preserved left ventricular ejection fraction. Mechanisms and patofyziology of heart failure with preserved ejection fraction is not fully elucidated. These patients have poor long-term prognosis. Therapy is symptomatic. Currently, no drug is available to improve prognosis.

Key words:
heart failure, ejection fraction, prognosis.

Sources

1. Cleland, J.F.K, Swedberg, K., Follath, F. et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. Eur. Heart J. 2003, 24, p. 442–463.

2. Yancy, C.W., Lopatin, M., Stevenson, L.W. et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. 2006, 47, p. 76-84.

3. Vasan, R.S. Diastolic heart failure. BMJ 2003, 327, p. 181-1183.

4. Hradec, J. Diastolické srdeční selhání. Diagnostika, epidemiologie, prognóza. Kardiol Rev. 2004, 4, p. 156-160.

5. Swedberg, K., Cleland, J., Dargie, H. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic heart Failure of the European Society of Cardiology. Eur. Heart J. 2005, 26, p. 1115-1140.

6. Melenovský, V., Kelner., J. Srdeční selhání se zachovalou ejekční frakcí levé komory. Intel. Akut. Kardiol. 2007, 6, p. 56-60.

7. Kupari, M., Lindroos, M., Iivanainen, A.M. et al. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in Helsinki Aging Study. J. Intern. Med. 1997, 24, p. 387-394.

8. Owan, T.E., Hodge, D.O., Herges, R.M. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006, 355, p. 251-259.

9. Tribouilloy, C., Rusinaru, D., Mahjoub, H. et al. Prognosis of HFpEF-5y prospective population study: Eur. Heart. J. 2008, 29, p. 339-347.

10. Yusuf, S., Pfeffer, M.S., Swedberg, K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet, 2003, 362, p. 777-781.

11. Flather, M.D., Shibata, M.C., Coats, A.J. et al. Randomized trial to determinate the effect of nrbivolol on mortality and cardiovascular hospital admission in eldery patients with heart failure (SENIORS). Eur. Heart J. 2005, 26, p. 215-225.

12. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997, 336, p. 525-533.